Mammogen Extends Breast Cancer Trial to Florida
Mammogen has partnered with MammoLink to offer its KATELYN-ERIN blood-based breast cancer detection study through mobile imaging units across Florida.
Updated on Nov. 3, 2026 in Cancer
Live Poll
Would you trust a blood test alongside mammograms to screen for breast cancer?
Mammogen, a diagnostics developer based in Newport Beach, California, has partnered with Florida mobile breast imaging provider MammoLink to extend the KATELYN-ERIN trial. The study evaluates a blood-based RNA assay for breast cancer detection in women across Florida communities.
Why it matters
Dense breast tissue can make cancers harder to detect on mammography, and Mammogen is developing its genTRU-breast assay to complement imaging for these women. Florida residents gain access to participate in the trial through local mobile screening services.
The prospective genTRU-breast study enrolls about 2,600 women, with assay performance measured against biopsy-confirmed pathology. The source does not report interim results, and the study's final outcomes remain unknown.
The players
Mammogen
Mammogen is a diagnostics company based in Newport Beach, California, developing the genTRU-breast blood-based assay for breast cancer detection.
MammoLink
MammoLink is a Florida mobile breast imaging provider operating six 3D mammography units across the state.
The details
The KATELYN-ERIN trial evaluates a blood-based RNA assay designed to detect breast cancer. MammoLink will deliver the trial through its network of six mobile 3D mammography units across Florida communities.
Timeline
November 3, 2026: Mammogen and MammoLink announce the partnership extending the KATELYN-ERIN trial.
Health Landscape
The KATELYN-ERIN trial extends the search for blood-based alternatives to imaging for women with dense breast tissue. The expansion into Florida brings this research to mobile screening settings outside traditional clinical centers.
Women in Florida communities served by MammoLink may be able to participate in the trial through mobile 3D mammography visits. Participation could offer an additional screening option for women with dense breast tissue, though the source does not confirm eligibility criteria.
The takeaway
Women with dense breast tissue may benefit from asking their providers about additional screening options beyond mammography. Trial participation details should be confirmed directly with MammoLink.
Further reading
For more on breast cancer detection research, see Cancer coverage.
Source note: This article includes information reported by AuntMinnie.
Live Poll
Would you trust a blood test alongside mammograms to screen for breast cancer?
